VIELA BIO, INC. Financing Cash Flow
VIELA BIO, INC. reported Financing Cash Flow of $159.58 million for the 12-month period ending 2020-12-31, per its 10-K filed 2021-03-01.
Discontinued › Cash Flow › Financing Activities
us-gaap:NetCashProvidedByUsedInFinancingActivities · last filed 2021-03-01
- VIELA BIO, INC. net cash provided by (used in) financing activities for the quarter ending 2020-12-31 was $215.00K, a 99.87% decline year-over-year.
- VIELA BIO, INC. net cash provided by (used in) financing activities for the quarter ending 2020-09-30 was -$93.00K, a 100.12% decline year-over-year.
- VIELA BIO, INC. net cash provided by (used in) financing activities for the quarter ending 2020-06-30 was $159.35M, a 110.07% increase year-over-year.
- VIELA BIO, INC. net cash provided by (used in) financing activities for the quarter ending 2020-03-31 was $102.00K, a 99.15% decline year-over-year.
- VIELA BIO, INC. net cash provided by (used in) financing activities for fiscal 2020 was $159.58M, a 50.97% decline from fiscal 2019.
- VIELA BIO, INC. net cash provided by (used in) financing activities for fiscal 2019 was $325.45M, a 8.39% increase from fiscal 2018.
- VIELA BIO, INC. net cash provided by (used in) financing activities for fiscal 2018 was $300.25M.
| Period end | Net Cash Provided by (Used in) Financing Activities 3 month | Net Cash Provided by (Used in) Financing Activities 6 month | Net Cash Provided by (Used in) Financing Activities 9 month | Net Cash Provided by (Used in) Financing Activities 12 month |
|---|---|---|---|---|
| 2020-12-31 | $215.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-01 | $122.00K derived: sum of 2 quarters · filed 2021-03-01 | $159.47M derived: sum of 3 quarters · filed 2021-03-01 | $159.58M 10-K · filed 2021-03-01 |
| 2020-09-30 | -$93.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-10 | $159.26M derived: sum of 2 quarters · filed 2020-11-10 | $159.36M 10-Q · filed 2020-11-10 | $318.85M derived: sum of 4 quarters · filed 2021-03-01 |
| 2020-06-30 | $159.35M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-12 | $159.46M 10-Q · filed 2020-08-12 | $318.94M derived: sum of 3 quarters · filed 2021-03-01 | $397.05M derived: sum of 4 quarters · filed 2021-03-01 |
| 2020-03-31 | $102.00K 10-Q · filed 2020-05-13 | $159.59M derived: sum of 2 quarters · filed 2021-03-01 | $237.69M derived: sum of 3 quarters · filed 2021-03-01 | $313.55M derived: sum of 4 quarters · filed 2021-03-01 |
| 2019-12-31 | $159.49M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-01 | $237.59M derived: sum of 2 quarters · filed 2021-03-01 | $313.45M derived: sum of 3 quarters · filed 2021-03-01 | $325.45M 10-K · filed 2021-03-01 |
| 2019-09-30 | $78.11M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-10 | $153.96M derived: sum of 2 quarters · filed 2020-11-10 | $165.96M 10-Q · filed 2020-11-10 | $183.96M derived: sum of 4 quarters · filed 2021-03-01 |
| 2019-06-30 | $75.86M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-12 | $87.86M 10-Q · filed 2020-08-12 | $105.86M derived: sum of 3 quarters · filed 2021-03-01 | |
| 2019-03-31 | $12.00M 10-Q · filed 2020-05-13 | $30.00M derived: sum of 2 quarters · filed 2021-03-01 | ||
| 2018-12-31 | $18.00M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-01 | $300.25M 10-K · filed 2021-03-01 | ||
| 2018-09-30 | $282.25M 10-Q · filed 2019-11-14 |